CHUNLI MEDICAL(SH:688236)2022-10-26 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥188,572,691.83, representing a decrease of 20.02% compared to the same period last year[8]. - Net profit attributable to shareholders for Q3 2022 was ¥52,725,036.03, an increase of 8.44% year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 46.80% to ¥24,953,166.18 in Q3 2022[8]. - Total operating revenue for Q3 2022 was CNY 759,964,308.26, an increase from CNY 718,393,295.82 in Q3 2021, representing a growth of approximately 5.4%[38]. - Net profit for Q3 2022 reached CNY 209,707,532.63, compared to CNY 204,175,210.23 in Q3 2021, reflecting a slight increase of approximately 2.5%[41]. - The total comprehensive income for the period was CNY 209,707,532.63, compared to CNY 204,175,210.23 in the same period last year, reflecting an increase of approximately 2.5%[43]. - Basic and diluted earnings per share were both CNY 0.55, down from CNY 0.59 in the previous year, indicating a decrease of about 6.8%[43]. Research and Development - Research and development expenses totaled ¥32,724,564.79 in Q3 2022, accounting for 17.35% of operating revenue, an increase of 4.22 percentage points year-on-year[11]. - Research and development expenses for Q3 2022 amounted to CNY 105,014,400.73, significantly higher than CNY 65,183,009.37 in Q3 2021, marking an increase of around 61.1%[38]. - The company emphasized increased investment in R&D to address performance pressure and slow growth due to centralized procurement[16]. - The company aims to enhance its market share and competitiveness through continuous R&D investment and expansion of market channels[16]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥3,109,675,551.59, reflecting a 3.67% increase from the end of the previous year[11]. - The total assets as of Q3 2022 were CNY 3,109,675,551.59, compared to CNY 2,999,657,361.45 in Q3 2021, showing an increase of approximately 3.7%[34]. - Total liabilities for Q3 2022 were CNY 487,987,384.89, down from CNY 530,579,974.97 in Q3 2021, indicating a decrease of about 8.0%[34]. - The company's equity attributable to shareholders increased to CNY 2,621,688,166.70 in Q3 2022 from CNY 2,469,077,386.48 in Q3 2021, representing a growth of approximately 6.2%[34]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥76,368,941.72, a significant decline of 231.72%[11]. - Cash inflow from operating activities totaled CNY 675,604,729.35, an increase from CNY 635,612,963.26, representing a growth of approximately 6.3%[46]. - Cash outflow from operating activities was CNY 751,973,671.07, compared to CNY 577,635,870.48 in the previous year, showing an increase of about 30%[46]. - The net cash flow from operating activities was negative at CNY -76,368,941.72, contrasting with a positive CNY 57,977,092.78 in the same period last year[46]. - Cash inflow from investment activities was CNY 1,550,365,527.41, significantly higher than CNY 6,786,876.71 in the previous year[46]. - The net cash flow from investment activities was CNY -534,949,975.29, worsening from CNY -176,539,833.18 in the previous year[46]. - Cash outflow from financing activities was CNY 58,832,013.62, compared to CNY 1,685,045.25 in the previous year, indicating a substantial increase[46]. Shareholder Information - The total number of A-share shareholders at the end of the reporting period was 17,101, while H-share shareholders numbered 18[24]. - The number of shares held by the top ten shareholders accounted for a significant portion of the total shares, with the largest shareholder holding 29.88%[20]. - The total number of shares held by HKSCC NOMINEES LIMITED was 94,680,695, representing a substantial foreign investment presence[20]. Strategic Focus - The company aims to enhance its market share as a leading orthopedic enterprise by actively responding to national policies and expanding its marketing network[25]. - The company is focused on strategic layout for future growth, emphasizing the importance of tracking market dynamics and enhancing operational efficiency[25]. - The company plans to continue investing in new product development and market expansion strategies to drive future growth[41].